Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies DOI Creative Commons
Jesús Prego-Domínguez, Fernando Laso-García, Nuria Palomar-Alonso

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 208 - 208

Published: Feb. 6, 2025

Background: Recombinant tissue plasminogen activator (rtPA) remains the standard thrombolytic treatment for ischemic stroke. Different types of nanoparticles have emerged as promising tools to improve benefits and decrease drawbacks this therapy. Among them, cell membrane-derived (CMD) nanomedicines gained special interest due their capability increase half-life particles in blood, biocompatibility, thrombus targeting. In order update evaluate efficacy these nanosystems, we performed a meta-analysis selected vivo preclinical studies. Methods: Preclinical studies stroke models been identified through search Pubmed database. We included rtPA-nanoparticles, which assessed infarct volume and/or neurological improvement. Nanosystems were compared with free (non-encapsulated) rtPA treatment. Standardized mean differences computed pooled estimate effect sizes lesion volumes scores. Subgroup analyses by risk bias, type nanoparticle, time administration also performed. Results: A total 18 publications meta-analysis. This was based on defined inclusion criteria. Our analysis revealed that rtPA-nanoparticles improved both scores Moreover, CMD showed better evolution other nanoparticles. Funnel plots exhibited asymmetry publication bias. Heterogeneity generally high, funnel plot Egger test some evidence bias did not achieve statistical significance trim-and-fill analysis. Conclusions: rtPA-encapsulating nanosystems shown scales treatment, had greatest beneficial effect.

Language: Английский

New Trends in Brain Shuttle Peptides DOI
Roger Prades, Meritxell Teixidò, Benjamí Oller‐Salvia

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence blood–brain barrier (BBB). This naturally protects brain and prevents therapeutics from reaching their targets efficiently. However, BBB allows passage nutrients other molecules that guarantee homeostasis through selective transport mechanisms present at BBB. These provide an opportunity for delivering therapeutic agents into using shuttles. Here we review progress shuttle peptide development 2015 until 2025. We highlight most utilized peptides describe trends in strategies develop new shuttles enhance efficiency. Additionally, compared them with types emphasize toward clinical translation.

Language: Английский

Citations

1
Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies DOI Creative Commons
Jesús Prego-Domínguez, Fernando Laso-García, Nuria Palomar-Alonso

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 208 - 208

Published: Feb. 6, 2025

Background: Recombinant tissue plasminogen activator (rtPA) remains the standard thrombolytic treatment for ischemic stroke. Different types of nanoparticles have emerged as promising tools to improve benefits and decrease drawbacks this therapy. Among them, cell membrane-derived (CMD) nanomedicines gained special interest due their capability increase half-life particles in blood, biocompatibility, thrombus targeting. In order update evaluate efficacy these nanosystems, we performed a meta-analysis selected vivo preclinical studies. Methods: Preclinical studies stroke models been identified through search Pubmed database. We included rtPA-nanoparticles, which assessed infarct volume and/or neurological improvement. Nanosystems were compared with free (non-encapsulated) rtPA treatment. Standardized mean differences computed pooled estimate effect sizes lesion volumes scores. Subgroup analyses by risk bias, type nanoparticle, time administration also performed. Results: A total 18 publications meta-analysis. This was based on defined inclusion criteria. Our analysis revealed that rtPA-nanoparticles improved both scores Moreover, CMD showed better evolution other nanoparticles. Funnel plots exhibited asymmetry publication bias. Heterogeneity generally high, funnel plot Egger test some evidence bias did not achieve statistical significance trim-and-fill analysis. Conclusions: rtPA-encapsulating nanosystems shown scales treatment, had greatest beneficial effect.

Language: Английский

Citations

0